Revenue Growth Driven by Core Business Expansion
Total revenue grew 5.8% YoY to $3.54B in Q1 FY2026, up from $3.35B in the prior-year period, indicating broad-based demand across LH's laboratory and diagnostic services segments.
LABCORP HOLDINGS INC. 已通过 8-K 新闻稿公布 Q2 2026 业绩，10-Q 提交后将自动生成完整 AI 解读。
上一期分析暂无中文版，相关内容以英文显示。
Labcorp公布2026年第二季度营收为37.3亿美元，同比增长5.8%，调整后每股收益为4.99美元，同比增长14.9%。
营收
37.31亿美元
每股收益 (non-GAAP)
4.99美元
业绩指引
对于2026全年度，Labcorp上调了业绩指引，预计企业营收增长率在5.4%至6.3%之间（营收为147.10亿美元至148.27亿美元），调整后每股收益为18.10美元至18.55美元。
来源：SEC Form 8-K（Item 2.02），EX-99.1 press release。数字为公司自报，预期值来自 Finnhub 分析师一致预期。这是当日快照——完整 AI 解读（管理层讨论、风险、审计意见）将在 10-Q/10-K 提交后自动生成。
想第一时间拿到完整解读？ 关注 LABCORP HOLDINGS INC.，完整报告生成后我们会通知你。
摘自 Q1 2026 10-Q 中的管理层讨论：
Total revenue grew 5.8% YoY to $3.54B in Q1 FY2026, up from $3.35B in the prior-year period, indicating broad-based demand across LH's laboratory and diagnostic services segments.
Operating income rose 16.8% YoY to $380.8M while SG&A expenses grew only 0.9% to $551.0M, demonstrating strong operating leverage as revenue growth significantly outpaced overhead cost increases. Operating margin expanded approximately 100 basis points to 10.8%.
Net income surged 30.5% YoY to $277.8M, with diluted EPS rising 32.9% to $3.35 from $2.52, reflecting both improved profitability and the benefit of share repurchases totaling $98.0M in the quarter (no buybacks in prior-year period).
Revenue
35.38亿美元
+5.75% 同比
EPS (Diluted)
3.35美元
+32.94% 同比
Gross Margin
28.7%
+0.3 个百分点 同比
Operating Income
3.81亿美元
+16.81% 同比
将 LH 加入关注列表，10-Q 提交后几分钟内即可在邮箱收到 AI 解读。